← All trials
NCT00680940
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2008
- Primary completion
- Dec 1, 2010
- Completion date
- Dec 1, 2010
- First posted
- —
- Last posted
- —
- Enrollment
- 221
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Cadila HealthcareLead sponsor
- Postgraduate Institute of Medical Education and ResearchOverall official - principal investigator
- Acharya Tulsi Regional Cancer Treatment & Research InstituteOverall official - principal investigator
- Patel Hospital Pvt. Ltd.Overall official - principal investigator
- Choithram Hospital and Research CentreOverall official - principal investigator
- Chittaranjan National Cancer InstituteOverall official - principal investigator
- Netaji Subhash Chandra Bose Cancer Research InstituteOverall official - principal investigator
- Bankura Sammilani Medical CollegeOverall official - principal investigator
- Gujarat Cancer & Research InstituteOverall official - principal investigator
- R.S.T. Cancer Hospital & Research CentreOverall official - principal investigator
- GKNM Hospital, Coimbatore, IndiaOverall official - principal investigator
- Indira Ghandhi Institute of Medical ScienceOverall official - principal investigator
- MNJ Cancer Hospital HyderabadOverall official - principal investigator
- B.P. Poddar Hospital and Medical Research Ltd.Overall official - principal investigator
- Malabar Institute of Medical SciencesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.